Form 4: RxSight Executive Eric Weinberg Acquires Stock Options
SEC Form 4 Filing
Eric Weinberg, Co-President and Chief Commercial Officer of RxSight, Inc., was granted stock options to purchase 125,000 shares of common stock on February 27, 2025.
Summary
- On February 27, 2025, Eric Weinberg, Co-President and Chief Commercial Officer of RxSight, Inc., acquired stock options for 125,000 shares.
- The exercise price of these options is $28.21 per share.
- The options vest monthly over a four-year period, starting on February 27, 2025, contingent upon Weinberg's continued service to the company.
- The options expire on February 26, 2035.
Sentiment
Score: 7
Explanation: The sentiment is neutral to slightly positive. The granting of stock options is a routine event, but it signals confidence in the executive and aligns his interests with the company's success.
Positives
- The granting of stock options to a key executive like Eric Weinberg aligns his interests with those of the shareholders, incentivizing him to contribute to the company's long-term success.
Risks
- The vesting of the stock options is contingent upon Eric Weinberg's continued service to RxSight, Inc.
- If he leaves the company before the options are fully vested, he will forfeit the unvested portion.
Future Outlook
The document does not contain specific forward-looking statements beyond the vesting schedule of the stock options.
Industry Context
Stock option grants are a common form of executive compensation in the medical device industry, used to attract and retain talent and align management's interests with shareholder value.
Comparison to Industry Standards
- Stock option grants are a standard component of executive compensation packages in the medical device industry.
- Companies like Alcon, Johnson & Johnson (Ethicon), and Bausch + Lomb also utilize stock options to incentivize their executives.
- The size of the grant (125,000 shares) and the vesting schedule (4 years) appear to be within typical ranges for similar roles in comparable companies.
Stakeholder Impact
- Shareholders may view the stock option grant positively as it incentivizes management to increase shareholder value.
- Employees may see it as a sign of the company's commitment to its leadership.
Key Dates
| Date | Description |
|---|---|
| 02/27/2025 | Date of the stock option grant and Vesting Commencement Date. |
| 02/26/2035 | Expiration date of the stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.